HALO Stock Overview
Halozyme Therapeutics, Inc, una empresa de plataformas tecnológicas biofarmacéuticas, investiga, desarrolla y comercializa enzimas y dispositivos patentados en Estados Unidos, Suiza, Bélgica, Japón y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Halozyme Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.07 |
| 52 Week High | US$45.00 |
| 52 Week Low | US$29.85 |
| Beta | 1.26 |
| 1 Month Change | -1.58% |
| 3 Month Change | 15.66% |
| 1 Year Change | 7.15% |
| 3 Year Change | -3.97% |
| 5 Year Change | 148.31% |
| Change since IPO | 889.64% |
Recent News & Updates
Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Recent updates
Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Dec 09Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today
Sep 08Halozyme Therapeutics raises $625M through convertible senior notes due 2028
Aug 16Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off
Aug 03Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jul 26Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Jun 10Halozyme: Antares Pharma Bolsters Growth Prospects
May 19Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Apr 25Shareholder Returns
| HALO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | -4.5% | -1.0% |
| 1Y | 7.1% | 3.6% | 26.0% |
Rentabilidad frente al sector: HALO superó al sector US Biotechs , que obtuvo un rendimiento del 2.9% el año pasado.
Rentabilidad vs. Mercado: HALO obtuvo unos resultados inferiores a los del mercado US, que fue del 14.1% el año pasado.
Price Volatility
| HALO volatility | |
|---|---|
| HALO Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: HALO no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HALO (6%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 373 | Helen Torley | https://halozyme.com |
Halozyme Therapeutics, Inc, una empresa de plataformas tecnológicas biofarmacéuticas, investiga, desarrolla y comercializa enzimas y dispositivos patentados en Estados Unidos, Suiza, Bélgica, Japón y a escala internacional. Los productos de la empresa se basan en la enzima hialuronidasa humana recombinante patentada (rHuPH20) que permite la administración de productos biológicos inyectables, como anticuerpos monoclonales y otras moléculas terapéuticas, así como pequeñas moléculas y fluidos. Ofrece Hylenex recombinante, una formulación de rHuPH20 para facilitar la administración subcutánea (SC) de fluidos con el fin de lograr la hidratación para mejorar la dispersión y absorción de otros fármacos inyectados en la urografía SC y para mejorar la reabsorción de agentes radiopacos; rilpivirina, cabotegravir y N6LS BNAB para el tratamiento del VIH; ocrelizumab para la esclerosis múltiple; XYOSTED, una inyección para la administración SC de terapia de sustitución de testosterona; y ATRS-1902, un producto patentado de combinación de fármaco y dispositivo.
Halozyme Therapeutics, Inc. Fundamentals Summary
| HALO fundamental statistics | |
|---|---|
| Market cap | US$5.22b |
| Earnings (TTM) | US$281.59m |
| Revenue (TTM) | US$829.25m |
18.5x
P/E Ratio6.3x
P/S RatioIs HALO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HALO income statement (TTM) | |
|---|---|
| Revenue | US$829.25m |
| Cost of Revenue | US$268.72m |
| Gross Profit | US$560.53m |
| Other Expenses | US$278.94m |
| Earnings | US$281.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.22 |
| Gross Margin | 67.59% |
| Net Profit Margin | 33.96% |
| Debt/Equity Ratio | 1,788.9% |
How did HALO perform over the long term?
See historical performance and comparison